Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Akeso
Condition: Hepatocellular Carcinoma
NCT04172571
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Completed No Results Found Signal
Operational burden: None
Stopped reason
Context when available
No stop reason available in the current public record.